Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray
Category: #health  By Mateen Dalal  Date: 2019-07-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray

The trial is designed to assess the efficacy and safety of OC-01 for treating dry eye disease

Reports confirm that Oyster Point Pharma, a clinical-stage biopharmaceutical company, has recently announced that the first subject has been enrolled in the Phase 3 ONSET-2 clinical study of OC-01 Nasal Spray to treat the symptoms and signs of dry eye disease.

According to CEO and President of Oyster Point Pharma, Jeffrey Nau, Ph.D., M.M.S., after successfully completing the registrational Phase 2b clinical study i.e. ONSET-1, the company has announced the commencement of the second registrational trial, ONSET-2.

It is believed that OC-01 has the potential to change the method used by eye care physicians to treat patients with dry eye disease, owing to the fast onset of action in surging natural tear film production, the capability to substantially improve both symptoms and signs of dry eye disease, and a promising tolerability profile.

The innovative delivery of OC-01 as a nasal spray spares the ocular surface and allows the product’s novel mechanism of action, offering unique benefits to patients and eye care practitioners.

Reportedly, the ONSET-2 clinical trial is a double-masked, randomized, multicentre, placebo-controlled clinical study to assess the efficacy and safety of OC-01 nasal spray for treating the symptoms and signs of dry eye disease.

The study, which will recruit around 750 subjects at around 20 U.S. centers, will investigate two dosages of OC-01 nasal spray, 1.2 mg/ml, and 0.6mg/ml, as compared to placebo nasal spray. The pre-specified primary endpoint of the clinical trial will be the evaluation of tear production as calculated by the percentage of subjects showing a 10 mm or bigger change at week 4 from baseline Schirmer’s Score.

A member of medical advisory board of Oyster Point Pharma and an ophthalmologist at Virginia Eye Consultants, Elizabeth Yeu, M.D., stated that it is inspiring to view the progress Oyster Point is achieving in the development of OC-01. There is a substantial requirement for therapeutic options that can successfully benefit a wide population of patients with dry eye disease.

 

Source Credits: https://oysterpointrx.com/oyster-point-pharma-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

U.S. representatives to discuss Facebooks’ Libra with Swiss authorities
U.S. representatives to discuss Facebooks’ Libra with Swiss authorities
By Mateen Dalal

U.S. House of Representatives will discuss its concern on cryptocurrency with FDPIC (Federal Data Protection and Information Commissioner) Adrian Lobsiger.   The discussion will mainly involve Facebook’s soon to be launched Libra block...

Delta and Virgin Atlantic to expand transatlantic services by 2020
Delta and Virgin Atlantic to expand transatlantic services by 2020
By Mateen Dalal

This will be the first time that both the carriers will be serving Gatwick airport since their partnership in 2014 British airlines Virgin Atlantic and the American airline Delta recently announced increased services between the US and UK by the yea...

Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
By Mateen Dalal

Startup Pikup.ai utilizes automated technologies like sensor fusion, computer vision, and Artificial Intelligence to offer AI-based solutions for businesses.   Ola is increasing company’s aim on utilizing deep technology and advanced a...